MCK — McKesson Corporation
Healthcare · ETF XLV · as of 2026-09-18
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business soluti...
Price & today
| Stock today | -0.56% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -0.31% |
Sector correlation
| 20-day correlation with XLV | 0.73 |
| 60-day correlation with XLV | 0.47 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $888.61 |
| 20 EMA | $886.86 |
| 50 EMA | $866.31 |
| EMA stack | BULLISH |
| RSI(14) | 47.5 |
| 52-week high distance | -12.45% |
| 52-week low distance | +37.31% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (3d) |
| Sector rank | #292 |
| Next earnings | 2026-11-03 (TNS, 45d) |
MarketSmith metrics - our compute
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
Company data - context read, not entry inputs
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | 7.07 | +13% | 93,651.0 | +21% |
| Feb-25 | 8.03 | +4% | 95,294.0 | +18% |
| May-25 | 10.12 | +64% | 90,823.0 | +19% |
| Aug-25 | 8.26 | +5% | 97,827.0 | +23% |
| Nov-25 | 9.86 | +39% | 103,150.0 | +10% |
| Feb-26 | 9.34 | +16% | 106,158.0 | +11% |
| May-26 | 11.69 | +16% | 96,295.0 | +6% |
| Aug-26 | 9.93 | +20% | 105,380.0 | +8% |
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 · AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
- Sep 16 · McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know Zacks Investment Research
- Sep 16 · McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know Yahoo
- Sep 16 · Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong Yahoo
- Sep 15 · Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years Benzinga
- Sep 15 · Did McKesson’s (MCK) EPS Hike and Oncology Push Just Redefine Its Investment Narrative? Yahoo
- Sep 14 · McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
- Sep 14 + McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal MarketBeat